12 results about "Aspartic Acid Proteases" patented technology

The invention provides an aspartic protease heat-resistant mutant and application thereof. Wherein the aspartic protease heat-resistant mutant comprises (a) a protein which is based on wild type aspartic protease pap1 as shown in SEQ ID NO: 1, is subjected to amino acid mutation on at least one of the following sites: G133, D159, S376, T198, T103, T144, L303 or A387, has aspartic protease activity and has higher heat resistance than that of the wild type aspartic protease pap1; or (b) a protein which has more than 80% of homology with the amino acid sequence limited in (a), has aspartic protease activity and has heat resistance higher than that of wild type aspartic protease pap1. The aspartic protease can solve the problem of poor heat resistance of aspartic protease in the prior art, and is suitable for the field of enzyme catalysis.

The invention relates to the technical field of biology, in particular to application of protein IbNFYA3 in regulation and control of soft rot resistance of sweet potatoes. It is found for the first time that the content of jasmonic acid and the content of aspartic protease can be remarkably increased through overexpression of the NFYA gene in a plant, so that soft rot bacteria can be effectively resisted, specifically, the invention provides an IbNFYA3 gene for coding an NFYA transcription factor (protein IbNFYA3), the gene is introduced into sweet potatoes to obtain a transgenic sweet potato plant with the overexpression of the IbNFYA3 gene, and the transgenic sweet potato plant has the advantages that the content of jasmonic acid and the content of aspartic protease can be effectively resisted; soft rot resistance identification is carried out on the transgenic sweet potato blocks, and it is found that compared with wild sweet potatoes, the soft rot resistance of the transgenic sweet potato blocks is obviously enhanced. Therefore, the IbNFYA3 protein and the coding gene thereof can regulate and control the soft rot resistance of plants, and can be used for cultivating transgenic plants with high disease resistance.

The present invention provides highly effective and safe means capable of preventing or treating an egg allergy in infants. An oral immunotolerance agent or a food composition for preventing or treating an egg allergy according to the present invention contains a degraded product of heat-denatured egg white with an aspartic protease (e.g. pepsin) or a metal protease (e.g. thermolysin).

The application relates to the field of genetic engineering, and discloses an Aspergillus niger, a construction method and application of the Aspergillus niger, and a method for producing citric acid and / or succinic acid. Aspergillus niger The Aspergillus niger is obtained by simultaneously overexpressing alpha-amylase and aspartic protease in a starting strain. The Aspergillus niger provided by the application can realize efficient degradation and conversion of starch by synergistically overexpressing amyA genes and pepA genes, solve the technical bottleneck that the original strain is limited in growth in a starch-based fermentation system and has insufficient acid production capacity, can efficiently produce succinic acid and citric acid by taking low-cost starch as the only carbon source, significantly reduce the industrial production cost of organic acid, and promote the green and sustainable upgrading of the fermentation industry.

An aspartic protease and the use of the aspartic protease in the hydrolysis of gluten. This protease can hydrolyze gluten and the gluten-derived immunogenic peptides at pH 2.0˜4.0. Also provided are methods for the production of the aspartic protease, including recombinant plasmids, transformants, and a purification method thereof; methods of using the aspartic protease to prepare drugs and oral enzyme supplements for treatment of diseases or discomforts related to gluten ingestion, such as celiac disease; and a method of using the asparic protease in food-processing process to remove or reduce gluten in foods or beverages.

The invention provides a sugarcane ScGIP1 gene, an encoded protein and application, and belongs to the technical field of genetic engineering. The nucleotide sequence of the ScGIP1 gene is as shown in SEQ ID NO. 1. The invention preliminarily reveals that the sugarcane aspartic protease ScGIP1 as a novel plant disease-resistant factor has potential application value in improvement of plant disease resistance, enriches functional cognition of aspartic protease in plant immune response, provides potential gene resources for disease prevention and control of sugarcane and other crops, and has broad application prospects. Good application prospects and popularization values are realized.

The present invention generally relates to aspartic proteases (EC 3.4.23) for producing cheese.

The present invention provides an aspartic protease mutant and its applications. The aspartic protease mutant includes: 1) a protein having an amino acid sequence with mutations at at least one of the following sites in SEQ ID NO: 4: R110, S38, S51, Q134, N169, V182, A183, V250, R322, N101, T113 or Q239, and having aspartic protease activity; or 2) a protein having an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% or more homology with the protein in 1), and having aspartic protease activity. Compared with the wild-type aspartic protease, the aspartic protease mutant of the present invention has the advantages of high specific activity and strong thermal stability, which is helpful for its wide application in the fields of food, medicine, feed and leather, etc.

The present invention discloses an aspartic protease from Rhizomucor miehei with rennet activity, its preparation method and application. The expression plasmid of this aspartic protease is constructed and transformed into Aspergillus niger for heterologous expression. The protease activity of the fermentation broth of the recombinant Aspergillus niger strain reaches 2000 U / mL, the protein content is 6.1 mg / mL, the optimal pH is 2.5, the optimal temperature is 40 °C, and it maintains a relatively high enzyme activity below 45 °C, and its substrate specificity is wide. This enzyme has a significant renneting effect, the rennet activity is 3894.1 SU / mg, and it specifically hydrolyzes the peptide bonds of Lys22-Ile23, Leu33-Ser34, Leu51-Ile52, Lys64-Pro65 and Phe105-Met106 of κ-casein. The aspartic protease of the present invention has good application value in the fields such as cheese making.

The present invention relates to the field of biotechnology, in particular to the application of the protein IbNFYA3 in regulating the resistance of sweet potato to soft rot. The present invention discovers for the first time that overexpressing the NFYA gene in plants can significantly increase the content of jasmonic acid and aspartic protease, thereby being able to effectively resist soft rot pathogens. Specifically, the present invention provides an IbNFYA3 gene encoding an NFYA transcription factor (protein IbNFYA3). After introducing this gene into sweet potato, transgenic sweet potato plants overexpressing the IbNFYA3 gene are obtained. When the transgenic sweet potato tubers are identified for their resistance to soft rot, it is found that compared with wild-type sweet potato, the transgenic sweet potato tubers have significantly enhanced resistance to soft rot. Thus, it can be seen that the IbNFYA3 protein and its encoding gene of the present invention can regulate the resistance of plants to soft rot and can be used to cultivate transgenic plants with high disease resistance.

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising said modified proteins, their preparation and the use of such compositions in medicine. More specifically, the present invention relates to a modified Sap2 (Secretory Aspartic Protease 2 of Candida albicans) protein. The modified Sap2 protein can be used as other antigens, in particular as a carrier protein for carbohydrate antigens or other antigens lacking T cell epitopes.

To provide a drug delivery system to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction.SOLUTION: A drug delivery system comprises a first active pharmaceutical ingredient (API) and a sustained delivery component, wherein the first API is a peptide derivative of ciliary neurotrophic factor (CNTF) comprising the peptide sequence DGGL, and the first API is a peptide represented by SEQ ID NO: 2 (peptide 21: Ac-DGGLAG-NH2). The drug delivery system is used for injection into mammal eyes.SELECTED DRAWING: None